Witryna8 sie 2024 · HERTHENA-Lung02 is a global, multicenter, open-label, phase 3 trial evaluating the efficacy and safety of patritumab deruxtecan (5.6 mg/kg) versus … WitrynaAbout HERTHENA-Lung01 HERTHENA-Lung01 is a global, multicenter, open-label, phase 2 study evaluating the safety and efficacy of patritumab deruxtecan in patients with locally advanced or metastatic NSCLC with an EGFR-activating mutation (exon 19 deletion or L858R) who have progressed after receiving at least one EGFR TKI and at …

A Study to Investigate the Efficacy and Safety of Trastuzumab ...

Witryna1 mar 2024 · HER3, a member of the human epidermal growth factor family, is detectable in the majority of EGFR- mutated NSCLC, and expression has been associated with … red mountain lake park

Press Release - Daiichi Sankyo

Witryna19 cze 2024 · Patritumab Deruxtecan Under Exploration in Phase 2 HERTHENA-Lung01 Trial for EGFR+ NSCLC. The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously … Witryna23 gru 2024 · The development program includes HERTHENA-Lung01, a pivotal phase 2 study in patients with locally advanced or metastatic EGFR-mutated NSCLC previously treated with a TKI and platinum-based chemotherapy; a phase 1/2 study in HER3 expressing metastatic breast cancer; a phase 1 study in combination with osimertinib … Witryna19 cze 2024 · The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy. red mountain laurel mirids